

Vanita Noronha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2486338/publications.pdf>

Version: 2024-02-01

226
papers

2,885
citations

257357

24
h-index

214721

47
g-index

227
all docs

227
docs citations

227
times ranked

3549
citing authors

#	ARTICLE	IF	CITATIONS
1	Systemic Therapy in Thyroid Cancer. Indian Journal of Surgical Oncology, 2022, 13, 68-80.	0.3	1
2	An Audit of Systemic Therapy in Medullary Carcinoma Thyroid. Indian Journal of Surgical Oncology, 2022, 13, 61-67.	0.3	0
3	Audit of Demographics, Treatment Patterns and Outcomes of Differentiated Thyroid Cancers Treated with Tyrosine Kinase Inhibitors. Indian Journal of Surgical Oncology, 2022, 13, 81-86.	0.3	0
4	Hypomagnesemia in patients with locally advanced head and neck cancer treated weekly cisplatin-incidence and impact on outcomes. Oral Oncology, 2022, 125, 105709.	0.8	0
5	Prospective Phase II Open-Label Randomized Controlled Trial to Compare Mandibular Preservation in Upfront Surgery With Neoadjuvant Chemotherapy Followed by Surgery in Operable Oral Cavity Cancer. Journal of Clinical Oncology, 2022, 40, 272-281.	0.8	22
6	Definitive and adjuvant radiation therapy for external auditory canal and temporal bone squamous cell carcinomas: Long term outcomes. Radiotherapy and Oncology, 2022, 170, 151-158.	0.3	5
7	Pembrolizumab weight based dosing – A call for policy change. Indian Journal of Medical and Paediatric Oncology, 2022, 43, 306-310.	0.1	2
8	Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with <sc>onceâ€œweek</sc> versus <sc>onceâ€œeveryâ€œ3â€œweeks</sc> cisplatin. Cancer Medicine, 2022, 11, 3939-3948.	1.3	2
9	G8 and VES-13 as screening tools for geriatric assessment and predictors of survival in older Indian patients with cancer. Journal of Geriatric Oncology, 2022, 13, 720-730.	0.5	7
10	Safety and efficacy of pembrolizumab with chemotherapy in locally advanced head and neck cancers. Oral Oncology, 2022, 127, 105824.	0.8	2
11	RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiation. Oral Oncology, 2022, 128, 105816.	0.8	2
12	Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer. Cancer Chemotherapy and Pharmacology, 2022, 89, 751-759.	1.1	5
13	Addressing the Needs of Older Adults With Cancer in Low- and Middle-Income Settings. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 384-393.	1.8	1
14	Safety of osimertinib in adult patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: Results from a Phase IV study in India. Indian Journal of Cancer, 2022, 59, 1.	0.2	0
15	Translation and Validation of COST - FACIT (Version 2) Questionnaire into Hindi and Marathi to Assess Financial Toxicity in Indian Cancer Patients. South Asian Journal of Cancer, 2022, 11, 097-104.	0.2	2
16	Comprehensive Development and Implementation of Good Laboratory Practice for NGS Based Targeted Panel on Solid Tumor FFPE Tissues in Diagnostics. Diagnostics, 2022, 12, 1291.	1.3	6
17	Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation. Translational Oncology, 2022, 22, 101461.	1.7	3
18	Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer. JCO Global Oncology, 2022, , .	0.8	10

#	ARTICLE	IF	CITATIONS
19	Oral metronomic therapy in head and neck cancer – Authors' reply. <i>The Lancet Global Health</i> , 2021, 9, e21.	2.9	0
20	Effect of Early Palliative Care on Quality of Life of Advanced Head and Neck Cancer Patients: A Phase III Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1228-1237.	3.0	14
21	Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer. <i>BMJ Open</i> , 2021, 11, e041345.	0.8	3
22	Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 1–5 sites of oligometastatic non-small cell lung cancer: a study protocol of phase III randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e043628.	0.8	6
23	Making the Best of Limited Resources: Improving Outcomes in Head and Neck Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 279-289.	1.8	4
24	Intensity-modulated radiation therapy for nasal cavity and paranasal sinus tumors: Experience from a single institute. <i>Head and Neck</i> , 2021, 43, 2045-2057.	0.9	4
25	Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations. <i>Oncotarget</i> , 2021, 12, 578-588.	0.8	13
26	Distress Screening in Head and Neck Cancer Patients Planned for Cancer-Directed Radiotherapy. <i>Laryngoscope</i> , 2021, 131, 2023-2029.	1.1	6
27	Study of Treatment Outcome in Adults with TFE-Related RCC. <i>South Asian Journal of Cancer</i> , 2021, 10, 92-96.	0.2	0
28	Immune checkpoint inhibitors in patients with solid tumors and poor performance status. <i>Medicine (United States)</i> , 2021, 100, e25115.	0.4	10
29	Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1234-1242.	0.8	178
30	Adolescent–adult nonmetastatic Ewing sarcoma—Experience from a large developing country. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29081.	0.8	3
31	Post hoc analysis of a randomized controlled trial comparing concurrent chemoradiation with cisplatin versus nimotuzumab-cisplatin, focusing on acute oral mucositis. <i>Journal of the Egyptian National Cancer Institute</i> , 2021, 33, 12.	0.6	1
32	Advances in pharmacotherapy for head and neck cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2007-2018.	0.9	5
33	ADME gene polymorphisms do not influence the pharmacokinetics of docetaxel: Results from a population pharmacokinetic study in Indian cancer patients. <i>Cancer Medicine</i> , 2021, 10, 4948-4956.	1.3	3
34	Locoregional recurrence after cystectomy in muscle invasive bladder cancer: Implications for adjuvant radiotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 496.e9-496.e15.	0.8	8
35	An observational study to evaluate factors predicting survival in patients of non-small cell lung cancer with poor performance status in resource-constrained settings. <i>Ecancermedicalscience</i> , 2021, 15, 1274.	0.6	1
36	Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs. <i>Translational Oncology</i> , 2021, 14, 101111.	1.7	2

#	ARTICLE	IF	CITATIONS
37	Primary mediastinal germ cell tumours with high prevalence of somatic malignancy: An experience from a single tertiary care oncology centre. <i>Annals of Diagnostic Pathology</i> , 2021, 53, 151763.	0.6	2
38	287 OUTCOMES OF DEFINITIVE CHEMORADIOTHERAPY IN LONG SEGMENT ESOPHAGEAL CANCERS FROM A TERTIARY CANCER CENTRE IN INDIA. <i>Ecological Management and Restoration</i> , 2021, 34, .	0.2	0
39	782 PATTERNS OF FAILURE AND ADEQUACY OF CLINICAL TARGET VOLUME (CTV) MARGINS IN PATIENTS TREATED WITH DEFINITIVE CHEMO-RADIATION IN ESOPHAGEAL CANCER. <i>Ecological Management and Restoration</i> , 2021, 34, .	0.2	1
40	Aspiration pneumonia in head and neck cancer patients undergoing concurrent chemoradiation from India: Findings from a post hoc analysis of a phase 3 study. <i>Cancer Medicine</i> , 2021, 10, 6725-6735.	1.3	4
41	Weight loss and its impact on outcome in head and cancer patients during chemo-radiation. <i>Oral Oncology</i> , 2021, 122, 105522.	0.8	3
42	Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone – Additional data from a phase 3 trial. <i>Oral Oncology</i> , 2021, 122, 105517.	0.8	10
43	Validation of a novel causality assessment scale for adverse events in non-small cell lung carcinoma patients treated with platinum and pemetrexed doublet chemotherapy. <i>Therapeutic Advances in Drug Safety</i> , 2021, 12, 204209862199128.	1.0	1
44	A real-world data of Immune checkpoint inhibitors in solid tumors from India. <i>Cancer Medicine</i> , 2021, 10, 1525-1534.	1.3	17
45	Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation – a phase 3 study. <i>Ecancermedalscience</i> , 2021, 15, 1318.	0.6	1
46	The clinical utility and safety of short-course immune checkpoint inhibitors in multiple tumours – A real-world multicentric study from India. <i>International Journal of Cancer</i> , 2021, , .	2.3	5
47	Efficacy and safety of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral squamous cell carcinoma (OSCC). <i>Ecancermedalscience</i> , 2021, 15, 1325.	0.6	4
48	Prognostic Impact of Pattern of Mandibular Involvement in Gingivo-Buccal Complex Squamous Cell Carcinomas: Marrow and Mandibular Canal Staging System. <i>Frontiers in Oncology</i> , 2021, 11, 752018.	1.3	10
49	Older patients with cancer require and deserve more!. <i>Indian Journal of Cancer</i> , 2021, 58, 479.	0.2	0
50	A competing risk analysis of death patterns in male genitourinary cancer. <i>Cancer Reports</i> , 2020, 3, e1174.	0.6	2
51	Palliative chemotherapy in head and neck cancer: balancing between beneficial and adverse effects. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 17-29.	1.1	17
52	Patterns of failure and outcomes in cT4 Oral squamous cell carcinoma (OSCC) undergoing upfront surgery in comparison to Neo-Adjuvant Chemotherapy (NACT) followed by surgery: A Matched Pair analysis. <i>Oral Oncology</i> , 2020, 100, 104455.	0.8	9
53	Prognostic and predictive significance of nuclear HIF1 α expression in locally advanced HNSCC patients treated with chemoradiation with or without nimotuzumab. <i>British Journal of Cancer</i> , 2020, 123, 1757-1766.	2.9	12
54	Choices. <i>Acta Oncol\ddot{a}gica</i> , 2020, 59, 797-798.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Incremental value of endoscopic brush cytology in response assessment after chemo-irradiation for Esophageal cancer. <i>Journal of Gastrointestinal Cancer</i> , 2020, , 1.	0.6	0
56	Systemic therapy for limited stage small cell lung carcinoma. <i>Journal of Thoracic Disease</i> , 2020, 12, 6275-6290.	0.6	13
57	The role of chemotherapy in patients with small cell lung cancer and poor performance status. <i>Acta Oncol3gica</i> , 2020, 59, 1520-1527.	0.8	1
58	Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial. <i>The Lancet Global Health</i> , 2020, 8, e1213-e1222.	2.9	57
59	COVID19 in cancer patients on active systemic therapy 39 Outcomes from LMIC scenario with an emphasis on need for active treatment. <i>Cancer Medicine</i> , 2020, 9, 8747-8753.	1.3	29
60	The Day My Gut Feeling Led Me Astray. <i>New England Journal of Medicine</i> , 2020, 382, 1880-1881.	13.9	0
61	Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non40 small cell lung cancer (NSCLC) with brain metastases. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1427-1436.	0.8	5
62	Reply to T. Tanaka et al and F. Liang. <i>Journal of Clinical Oncology</i> , 2020, 38, 844-846.	0.8	0
63	Salvage surgery in head and neck cancer: Does it improve outcomes?. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1052-1058.	0.5	25
64	Aprepitant for Cough Suppression in Advanced Lung Cancer. <i>Chest</i> , 2020, 157, 1647-1655.	0.4	15
65	Beyond conventional chemotherapy, targeted therapy and immunotherapy in squamous cell cancer of the oral cavity. <i>Oral Oncology</i> , 2020, 105, 104673.	0.8	17
66	Clinical outcomes for nasopharyngeal cancer with intracranial extension after taxane41 based induction chemotherapy and concurrent chemo42 radiotherapy in the modern era. <i>World Journal of Otorhinolaryngology - Head and Neck Surgery</i> , 2020, 6, 25-33.	0.7	2
67	Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer. <i>Oncotarget</i> , 2020, 11, 399-408.	0.8	12
68	Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms: retrospective data from real-world settings. <i>Ecancermedalscience</i> , 2020, 14, 1038.	0.6	5
69	An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast43 ovarian cancer syndrome. <i>South Asian Journal of Cancer</i> , 2020, 09, 06-12.	0.2	6
70	Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer. <i>South Asian Journal of Cancer</i> , 2020, 09, 47-49.	0.2	0
71	Quality of life in patients with locally advanced head and neck cancer undergoing chemoradiation with once-a-week versus once-every-three-weeks cisplatin.. <i>Journal of Clinical Oncology</i> , 2020, 38, 12092-12092.	0.8	0
72	Association of immune-related adverse effects and survival in responders treated with immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15172-e15172.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience. South Asian Journal of Cancer, 2020, 09, 67-68.	0.2	0
74	A tertiary care audit of using abiraterone acetate in patients of metastatic castrate-resistant prostate cancer. South Asian Journal of Cancer, 2020, 09, 23-26.	0.2	1
75	Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience. South Asian Journal of Cancer, 2020, 09, 180-182.	0.2	1
76	Chemoradiation in Unresectable Oral Cavity Cancer: A Myth or Reality!. South Asian Journal of Cancer, 2020, 09, 195-198.	0.2	2
77	Lymphopenia during chemoradiation-foe or friend. Ecancermedicalsecience, 2020, 14, 1109.	0.6	0
78	Multidisciplinary brain metastasis clinic: is it effective and worthwhile?. Ecancermedicalsecience, 2020, 14, 1136.	0.6	0
79	A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer. Cancer, 2019, 125, 3184-3197.	2.0	73
80	Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer. EClinicalMedicine, 2019, 9, 19-25.	3.2	6
81	<p>Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis</p>. Lung Cancer: Targets and Therapy, 2019, Volume 10, 1-10.	1.3	29
82	Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer. Frontiers in Oncology, 2019, 9, 86.	1.3	71
83	A phase II randomized control trial of erlotinib in combination with celecoxib in patients with operable oral squamous cell carcinoma (OSCC): Erlor-Xib Study.. Journal of Clinical Oncology, 2019, 37, 6054-6054.	0.8	4
84	Low doses in immunotherapy: Are they effective?. Cancer Research Statistics and Treatment, 2019, 2, 54.	0.1	12
85	An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma. South Asian Journal of Cancer, 2019, 08, 159-165.	0.2	1
86	Bladder cancer demographics and outcome data from 2013 at a tertiary cancer hospital in India. Indian Journal of Cancer, 2019, 56, 54.	0.2	10
87	First-line immunotherapy in advanced non-small-cell lung cancer. Indian Journal of Medical and Paediatric Oncology, 2019, 40, 461.	0.1	0
88	QOL assessment in head and neck cancer patients undergoing neoadjuvant chemotherapy and its impact on overall survival.. Journal of Clinical Oncology, 2019, 37, e17519-e17519.	0.8	0
89	Neoadjuvant chemotherapy in technically unresectable adenocarcinoma of parotid. South Asian Journal of Cancer, 2019, 08, 185-188.	0.2	1
90	Palliative chemotherapy in carcinoma nasopharynx. South Asian Journal of Cancer, 2019, 08, 173-177.	0.2	1

#	ARTICLE	IF	CITATIONS
91	Use of lorlatinib subsequent to crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience. <i>South Asian Journal of Cancer</i> , 2019, 08, 211-225.	0.2	1
92	Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer. <i>Oncotarget</i> , 2019, 10, 6297-6307.	0.8	1
93	Metastatic Renal Cell Cancer—Systemic Therapy. <i>Indian Journal of Surgical Oncology</i> , 2018, 9, 97-104.	0.3	2
94	Altered fractionation radiotherapy combined with concurrent low-dose or high-dose cisplatin in head and neck cancer: A systematic review of literature and meta-analysis. <i>Oral Oncology</i> , 2018, 76, 52-60.	0.8	29
95	Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1064-1072.	0.8	229
96	Thromboembolic events in patients with advanced stage non-small cell lung cancer treated with platinum-based chemotherapy: a prospective observational study. <i>Ecancermedicalscience</i> , 2018, 12, 876.	0.6	5
97	Analysis of solid tumor mutation profiles in liquid biopsy. <i>Cancer Medicine</i> , 2018, 7, 5439-5447.	1.3	21
98	Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. <i>Cancer Cell</i> , 2018, 34, 792-806.e5.	7.7	102
99	Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2018, Volume 9, 1-11.	1.3	38
100	Results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6000-6000.	0.8	9
101	An Algorithm to Define the Optimum Biological Dose of Metronomic Chemotherapy. <i>Biometrical Letters</i> , 2018, 55, 1-15.	0.4	1
102	Prognostic significance of pretreatment sodium levels in patients of nonsmall cell lung cancer treated with pemetrexed-platinum doublet chemotherapy. <i>Journal of Cancer Research and Therapeutics</i> , 2018, 14, 1049.	0.3	7
103	Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?. <i>Lung India</i> , 2018, 35, 27.	0.3	3
104	Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer. <i>South Asian Journal of Cancer</i> , 2018, 07, 194-202.	0.2	1
105	Treatment outcomes of metastatic nonclear cell renal cell carcinoma: A single institution retrospective analysis. <i>South Asian Journal of Cancer</i> , 2018, 07, 226-230.	0.2	5
106	Quality of life and quality-adjusted time without toxicity in palliatively treated head-and-neck cancer patients. <i>South Asian Journal of Cancer</i> , 2018, 07, 249-252.	0.2	8
107	Patterns of epidermal growth factor receptor testing across 111 tertiary care centers in India: Result of a questionnaire-based survey. <i>South Asian Journal of Cancer</i> , 2018, 07, 203-206.	0.2	7
108	Phase III randomized trial comparing intravenous to oral iron in patients with cancer-related iron deficiency anemia not on erythropoiesis stimulating agents. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e129-e137.	0.7	6

#	ARTICLE	IF	CITATIONS
109	Outcomes with Palliative Weekly Paclitaxel in Advanced, Recurrent, and Metastatic Esophageal Cancer –Real World Experience. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 46-51.	0.1	0
110	Tyrosine kinase inhibitor versus physician choice chemotherapy in second-line epidermal growth factor receptor mutation non-small cell lung cancer: Post hoc analysis of randomized control trial. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 493.	0.1	0
111	Toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin ineligible head and neck cancer patients.. Journal of Clinical Oncology, 2018, 36, e18022-e18022.	0.8	0
112	Influence of hypothyroidism post chemo radiation on outcomes in head and neck cancer.. Journal of Clinical Oncology, 2018, 36, e18066-e18066.	0.8	0
113	Immunotherapy in advanced cancers and predictor factors for outcome: An Indian experience.. Journal of Clinical Oncology, 2018, 36, e15065-e15065.	0.8	1
114	Long-term survival outcomes of technically unresectable carcinoma maxilla postinduction chemotherapy. South Asian Journal of Cancer, 2018, 07, 213-214.	0.2	0
115	Chicken pox infection in patients undergoing chemotherapy: A retrospective analysis from a tertiary care center in India. Journal of Infection and Public Health, 2017, 10, 8-13.	1.9	4
116	Potential role of metronomic chemotherapy in the treatment of esophageal and gastroesophageal cancer. Cancer Letters, 2017, 400, 267-275.	3.2	5
117	Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma –Results From a Tertiary Cancer Center in India. Clinical Genitourinary Cancer, 2017, 15, e345-e355.	0.9	6
118	Neoadjuvant chemotherapy in geriatric head and neck cancers. Head and Neck, 2017, 39, 886-892.	0.9	5
119	Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. ESMO Open, 2017, 2, e000168.	2.0	48
120	Epidermal Growth Factor Receptor Mutational Status and Brain Metastases in Non-Small-Cell Lung Cancer. Journal of Global Oncology, 2017, 3, 208-217.	0.5	33
121	Incidence and impact of Dihydropyrimidine dehydrogenase gene mutation on neoadjuvant chemotherapy in head and neck cancers. Oral Oncology, 2017, 70, 73-74.	0.8	3
122	A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. Clinical Pharmacology in Drug Development, 2017, 6, 234-239.	0.8	2
123	P3.02b-055 Impact of Pemetrexed Chemotherapy in Exon 19 or Exon 21 Mutated NSCLC. Journal of Thoracic Oncology, 2017, 12, S1223.	0.5	1
124	P3.02b-058 Second-Line Therapy in EGFR Activating Mutation Positive Advanced NSCLC: Analysis from a Randomized Phase III First-Line Trial. Journal of Thoracic Oncology, 2017, 12, S1225.	0.5	0
125	P3.02b-065 Third Line Therapy in EGFR Positive Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S1229-S1230.	0.5	0
126	Results of a phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer. Oral Oncology, 2017, 75, 54-60.	0.8	11

#	ARTICLE	IF	CITATIONS
127	Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data. <i>Oncologist</i> , 2017, 22, 1056-1066.	1.9	122
128	Feasibility of molecular testing in a multicenter study with geographical variation in India: Epidermal growth factor receptor mutation as a model molecular test. <i>Asian Journal of Oncology</i> , 2017, 03, 039-044.	0.2	3
129	Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2903-2908.	1.0	29
130	Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?. <i>Chemotherapy Research and Practice</i> , 2017, 2017, 1-4.	1.6	1
131	EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1859-1863.	1.0	44
132	Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed&acaroncarboplatin chemotherapy. <i>Ecancermedicalsecience</i> , 2017, 11, 776.	0.6	2
133	Prognostic value of a patient-reported functional score versus physicianreported Karnofsky Performance Status Score in brain metastases. <i>Ecancermedicalsecience</i> , 2017, 11, 779.	0.6	12
134	Adherence to and Implementation of ASCO Antiemetic Guidelines in Routine Practice in a Tertiary Cancer Center in India. <i>Journal of Oncology Practice</i> , 2017, 13, e574-e581.	2.5	10
135	Survey of Implementation of Antiemetic Prescription Standards in Indian Oncology Practices and Its Adherence to the American Society of Clinical Oncology Antiemetic Clinical Guideline. <i>Journal of Global Oncology</i> , 2017, 3, 346-359.	0.5	3
136	Evolving Management Strategies and Controversies in Early-Stage Lung Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, 79-81.	2.5	0
137	Phase III randomized trial comparing weekly versus three-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6007-6007.	0.8	20
138	Results of a phase II randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6018-6018.	0.8	2
139	A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers. <i>South Asian Journal of Cancer</i> , 2017, 06, 011-014.	0.2	11
140	Efficacy of crizotinib in ALK mutant non-small cell lung cancers that are positive by IHC but negative by FISH compared to FISH positive cases. <i>Indian Journal of Cancer</i> , 2017, 54, 678.	0.2	6
141	A study to assess the feasibility of introducing early palliative care in ambulatory patients with advanced lung cancer. <i>Indian Journal of Palliative Care</i> , 2017, 23, 261.	1.0	7
142	EMERALD: Emergency visit audit of patients treated under medical oncology in a tertiary cancer center: Logical steps to decrease the burden. <i>South Asian Journal of Cancer</i> , 2017, 06, 186-189.	0.2	4
143	Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer. <i>South Asian Journal of Cancer</i> , 2017, 06, 143-146.	0.2	4
144	Kidney cancer demographics and outcome data from 2013 at a tertiary cancer hospital in India. <i>Indian Journal of Cancer</i> , 2017, 54, 601.	0.2	11

#	ARTICLE	IF	CITATIONS
145	Poor risk advanced renal cell carcinoma: Outcomes from a registry in a tertiary cancer center. Indian Journal of Medical and Paediatric Oncology, 2017, 38, 311.	0.1	0
146	Reference Data for Standardized Quality of Life Questionnaires in Indian Patients with Brain Metastases from Non-small Cell Lung Cancer: Results from a Prospective Study. Cureus, 2017, 9, e1149.	0.2	2
147	Feasibility and outcome of repeat biopsy upon progression on tyrosine kinase inhibitors in patients with EGFR mutation positive adenocarcinoma of lung-an Indian tertiary cancer centre experience.. Journal of Clinical Oncology, 2017, 35, e20628-e20628.	0.8	1
148	Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre. Case Reports in Oncology, 2016, 9, 506-515.	0.3	0
149	Neoadjuvant Chemotherapy in Locally Advanced and Borderline Resectable Nonsquamous Sinonasal Tumors (Esthesioneuroblastoma and Sinonasal Tumor with Neuroendocrine Differentiation). International Journal of Surgical Oncology, 2016, 2016, 1-8.	0.3	18
150	ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country. PLoS ONE, 2016, 11, e0160752.	1.1	28
151	Curative intent therapy in oligometastatic lung cancer with an unresectable primary with N3 nodes: case report and review of the literature. Lung Cancer Management, 2016, 5, 21-27.	1.5	0
152	Technically unresectable recurrent oral cancers: Is NACT the answer?. Oral Oncology, 2016, 56, e12-e14.	0.8	1
153	Efficacy and Safety of Induction Chemotherapy in Esophageal Cancer with Airway Involvement. Journal of Gastrointestinal Cancer, 2016, 47, 294-304.	0.6	6
154	Expectations and preferences for palliative chemotherapy in head and neck cancers patients. Oral Oncology, 2016, 63, 10-15.	0.8	16
155	Clinical Outcome in Definitive Concurrent Chemoradiation With Weekly Paclitaxel and Carboplatin for Locally Advanced Esophageal and Junctional Cancer. Oncology Research, 2016, 23, 183-195.	0.6	26
156	Extra-lymphatic filariasis at reconstructive surgery flap site recurrence of head and neck cancer. IDCases, 2016, 3, 8-9.	0.4	0
157	Health-related quality of life in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of the head and neck in India. Supportive Care in Cancer, 2016, 24, 1595-1602.	1.0	14
158	Effect of EGFR mutations on outcomes in NSCLC with brain metastases.. Journal of Clinical Oncology, 2016, 34, e20644-e20644.	0.8	1
159	Toxicity analysis of docetaxel, cisplatin, and 5-fluorouracil neoadjuvant chemotherapy in Indian patients with head and neck cancers. Journal of Community and Supportive Oncology, 2016, 14, 412-419.	0.1	2
160	Aggressive surgery in palliative setting of lung cancer: Is it helpful?. Indian Journal of Palliative Care, 2016, 22, 504.	1.0	1
161	Sunitinib-induced thrombotic microangiopathy. Journal of Cancer Research and Therapeutics, 2016, 12, 6.	0.3	8
162	Weekly paclitaxel as metronomic palliative chemotherapy in small cell lung cancer. South Asian Journal of Cancer, 2016, 05, 067-069.	0.2	7

#	ARTICLE	IF	CITATIONS
163	Lung cancer in the Indian subcontinent. South Asian Journal of Cancer, 2016, 05, 095-103.	0.2	63
164	Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?. South Asian Journal of Cancer, 2016, 05, 182-185.	0.2	12
165	Agreement analysis between three different short geriatric screening scales in patients undergoing chemotherapy for solid tumors. Journal of Cancer Research and Therapeutics, 2016, 13, 1023-1026.	0.3	1
166	A cross-sectional observation study regarding patients and their physician willingness to wait for driver mutation report in nonsmall-cell lung cancer. Indian Journal of Medical and Paediatric Oncology, 2016, 37, 74-78.	0.1	0
167	Survey of implementation of antiemetic prescription standards in Indian oncology practices and adherence to ASCO's antiemetic clinical guideline.. Journal of Clinical Oncology, 2016, 34, e18230-e18230.	0.8	0
168	Toxicity, tolerance and outcomes of carboplatin based CTRT (concurrent chemoradiation) in head and neck cancers in patients who were not fit for cisplatin based CTRT.. Journal of Clinical Oncology, 2016, 34, e17539-e17539.	0.8	0
169	Phase III open label randomized controlled trial comparing intravenous iron sucrose to oral ferrous sulphate (without erythropoiesis stimulating agents) in the treatment of cancer related iron deficiency anemia.. Journal of Clinical Oncology, 2016, 34, 10136-10136.	0.8	1
170	Neoadjuvant chemotherapy and surgical margin in technically unresectable buccal mucosa cancers. Oral Oncology, 2015, 51, e91-e92.	0.8	6
171	A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. Oral Oncology, 2015, 51, 279-286.	0.8	65
172	NACT in locally advanced oral cancers : Does HPV make a difference?. Journal of Clinical Oncology, 2015, 33, e17068-e17068.	0.8	2
173	Patterns of EGFR testing for lung cancer among tertiary care centers in India.. Journal of Clinical Oncology, 2015, 33, e19114-e19114.	0.8	2
174	Metronomic chemotherapy in platinum-insensitive failures and/or early failures postmultimodality management in oral cancers. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 161-165.	0.1	20
175	Maintenance pemetrexed in nonsmall cell lung carcinoma: Outcome analysis from a tertiary care center. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 238-242.	0.1	5
176	Comparison of postoperative complications in advanced head and neck cancer patients receiving neoadjuvant chemotherapy followed by surgery versus surgery alone. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 249-254.	0.1	2
177	Neoadjuvant chemotherapy in advanced sinonasal teratocarcinosarcoma with intracranial extension: Report of two cases with literature review. Journal of Cancer Research and Therapeutics, 2015, 11, 1003.	0.3	15
178	Excellent response to oral Metronomic chemotherapy in unresectable adenocarcinoma of external auditory canal. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 132-132.	0.1	0
179	Compliance to NACT in T4 oral cancers :The place, person, socioeconomic status or assistance.. Journal of Clinical Oncology, 2015, 33, e17534-e17534.	0.8	0
180	A cross sectional retrospective study regarding patients and their physician willingness to wait for driver mutation report in NSCLC.. Journal of Clinical Oncology, 2015, 33, e17532-e17532.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Epidemiology of male seminomatous (SGCT) and non-seminomatous germ cell tumours (NSGCT) and response to first line chemotherapy (CT) from a tertiary cancer centre in India.. Journal of Clinical Oncology, 2015, 33, e15553-e15553.	0.8	0
182	Prognostic importance of pretreatment sodium levels in patients of NSCLC treated with pemetrexed-platinum doublet chemotherapy.. Journal of Clinical Oncology, 2015, 33, e18510-e18510.	0.8	0
183	Neoadjuvant chemotherapy in technically unresectable carcinoma of external auditory canal. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 172-175.	0.1	3
184	High plasma exposure to pemetrexed leads to severe hyponatremia in patients with advanced non small cell lung cancer receiving pemetrexed-platinum doublet chemotherapy. Cancer Management and Research, 2014, 6, 261.	0.9	6
185	Side effects of Sorafenib and sunitinib: A new concern for dermatologist and oncologist. Indian Dermatology Online Journal, 2014, 5, 89.	0.2	7
186	Carcinomatous meningitis in non-small cell lung cancer: Palliation with intrathecal treatment. Indian Journal of Medical and Paediatric Oncology, 2014, 35, 75-78.	0.1	8
187	Weekly chemotherapy as Induction chemotherapy in locally advanced head and neck cancer for patients ineligible for 3 weekly maximum tolerable dose chemotherapy. Indian Journal of Cancer, 2014, 51, 20.	0.2	9
188	Induction Chemotherapy in Technically Unresectable Locally Advanced Carcinoma of Maxillary Sinus. Chemotherapy Research and Practice, 2014, 2014, 1-6.	1.6	23
189	The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients. Chemotherapy Research and Practice, 2014, 2014, 1-4.	1.6	24
190	Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise?. Urology Annals, 2014, 6, 18.	0.3	5
191	High pathologic complete remission rate from induction docetaxel, platinum and fluorouracil (DCF) combination chemotherapy for locally advanced esophageal and junctional cancer. Medical Oncology, 2014, 31, 188.	1.2	11
192	Tolvaptan. South Asian Journal of Cancer, 2014, 03, 182-184.	0.2	6
193	Neoadjuvant chemotherapy in very locally advanced technically unresectable oral cavity cancers.. Journal of Clinical Oncology, 2014, 32, e17033-e17033.	0.8	0
194	A phase II study comparing metronomic chemotherapy with chemotherapy (single-agent cisplatin), in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of head and neck.. Journal of Clinical Oncology, 2014, 32, 6017-6017.	0.8	1
195	The X factor: An Indian perspective on women in academic oncology. Journal of Cancer Research and Therapeutics, 2013, 9, 552.	0.3	3
196	Stage IV lung cancer: Is cure possible?. Indian Journal of Medical and Paediatric Oncology, 2013, 34, 121.	0.1	8
197	Resistant metastatic penile carcinoma and response to biochemotherapy with paclitaxel and epidermal growth factor receptor monoclonal antibody, nimotuzumab. Indian Journal of Medical and Paediatric Oncology, 2013, 34, 24.	0.1	5
198	Case of childhood laryngeal papillomatosis with metastatic carcinoma esophagus in adulthood. Indian Journal of Medical and Paediatric Oncology, 2013, 34, 34-37.	0.1	3

#	ARTICLE	IF	CITATIONS
199	A diagnostic dilemma in a patient with lymphoma. Indian Journal of Medical and Paediatric Oncology, 2013, 34, 114-116.	0.1	1
200	Primary mediastinal seminoma; resistance and relapse: An aggressive entity. Indian Journal of Medical and Paediatric Oncology, 2013, 34, 309-312.	0.1	9
201	Oesophageal carcinoma presenting with a synchronous asymptomatic colon carcinoma. Indian Journal of Medical and Paediatric Oncology, 2013, 34, 117.	0.1	0
202	Frequency of EGFR Mutations in 907 Lung Adenocarcinoma Patients of Indian Ethnicity. PLoS ONE, 2013, 8, e76164.	1.1	94
203	EGFR Mutations in Indian Lung Cancer Patients: Clinical Correlation and Outcome to EGFR Targeted Therapy. PLoS ONE, 2013, 8, e61561.	1.1	61
204	Crizotinib: A comprehensive review. South Asian Journal of Cancer, 2013, 2, 91.	0.2	115
205	A systematic approach to diagnosis of cystic brain lesions. South Asian Journal of Cancer, 2013, 2, 98.	0.2	24
206	Geriatric oncology: The need of the hour. South Asian Journal of Cancer, 2013, 02, 200-201.	0.2	1
207	The cure for a racing heart. South Asian Journal of Cancer, 2013, 2, 169.	0.2	0
208	Neoadjuvant DCF in resectable esophageal cancer: Single-center experience.. Journal of Clinical Oncology, 2013, 31, 124-124.	0.8	0
209	Quality of life and safety profile of pemetrexed-platinum doublet in Indian adult chemo-naive NSCLC patients.. Journal of Clinical Oncology, 2013, 31, e19118-e19118.	0.8	0
210	Predicting complications of chemotherapy-induced febrile neutropenia: A single-center experience.. Journal of Clinical Oncology, 2013, 31, e20678-e20678.	0.8	1
211	Acute toxicity of neoadjuvant chemotherapy in oral cavity cancers: Can it be predicted?. Journal of Clinical Oncology, 2013, 31, e17027-e17027.	0.8	0
212	Are three drugs better than two and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers?. Journal of Clinical Oncology, 2013, 31, 6085-6085.	0.8	2
213	Confusion worse confounded. South Asian Journal of Cancer, 2013, 02, 278-278.	0.2	0
214	Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer. Urology Annals, 2012, 4, 150.	0.3	39
215	Primitive Neuroectodermal Tumor of Ovary in a Young Lady, Confirmed with Molecular and Cytogenetic Results—A Rare Case Report with a Diagnostic and Therapeutic Challenge. Pathology and Oncology Research, 2012, 18, 1101-1106.	0.9	14
216	A fresh look at oncology facts on south central Asia and SAARC countries. South Asian Journal of Cancer, 2012, 01, 01-04.	0.2	49

#	ARTICLE	IF	CITATIONS
217	Thyroid cancer in Gardner's syndrome: Case report and review of literature. South Asian Journal of Cancer, 2012, 01, 43-47.	0.2	7
218	The changing landscape of hormonal therapy in castration-resistant prostate cancer. South Asian Journal of Cancer, 2012, 01, 53-55.	0.2	0
219	The changing landscape of cancer in rural setting. South Asian Journal of Cancer, 2012, 01, 58-58.	0.2	0
220	Rare metastatic prostatic malignancy: A case report and approach to management. Indian Journal of Medical and Paediatric Oncology, 2011, 32, 233.	0.1	1
221	Metastatic myoepithelial carcinoma of the vulva treated with carboplatin and paclitaxel. Lancet Oncology, The, 2006, 7, 270-271.	5.1	48
222	Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: Case study and review of the literature. Neuro-Oncology, 2006, 8, 280-283.	0.6	62
223	Primary non-Hodgkin's lymphoma of the liver. Critical Reviews in Oncology/Hematology, 2005, 53, 199-207.	2.0	172
224	Oxaliplatin Induces a Delayed Immune-Mediated Hemolytic Anemia: A Case Report and Review of the Literature. Clinical Colorectal Cancer, 2005, 5, 283-286.	1.0	23
225	Prognostic Impact of Baseline Liver Metastasis in ALK Fusion-Positive Metastatic Lung Cancer: A Retrospective Review. South Asian Journal of Cancer, 0, , .	0.2	1
226	Change in Pattern of Failure in Head and Neck Cancer. Journal of Clinical Oncology, 0, , .	0.8	1